Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
Less than a month into his presidency, Donald Trump has already stirred controversy with a flurry of new executive orders, including attacks on Diversity, Equity and Inclusion programs and today’s closure of the United States Agency for International Development (USAID) offices, which oversee foreign aid, HIV and AIDS care included.
Managed Healthcare Executive sat down with Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director at the HIV+Hepatitis Policy Institute in Washington, D.C., to find out what else may be in store over the next four years.
Abrigo said he is worried about a revival of the 1873 Comstock Act, named for the anti-vice crusader, Anthony Comstock. It prevents anything “obscene” from being sent in the mail. Abrigo said proponents’ priority is abortion but added that it could be used to target information about condoms or preexposure prophylaxis, both of which impact HIV care.
“HIV is so intertwined with racial justice and the LGBTQ community, and those are the two communities most at risk,” Abrigo said in the Managed Healthcare Executive interview. “An attack on people of color, especially Black women, and attacks on LGBTQ communities, especially the trans community, will disproportionately harm and hurt folks living with HIV.”
Schmid emphasized that his organization is working with the current administration to continue the Ending the HIV Epidemic in the U.S. initiative, which was set up under Trump.
“You can't take away healthcare from people living with HIV,” Schmid said in the Managed Healthcare Executive interview. “It is a lifetime requirement, and unfortunately, we don't have the private insurance, adequate private insurance, adequate Medicaid programs to ensure that people have that care, treatment, and the support services, the case management to make sure people stay adherent to their medications.”
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
Trump Budget Axes CDC HIV Prevention, Shifts Care, Experts Warn of Risks
June 10th 2025Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.
Read More
Most HIV Patients Trust Their Providers But Don’t Always Feel Heard, Survey Says
May 27th 2025Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.
Read More